Published in J Acquir Immune Defic Syndr on March 01, 2012
Pharmacokinetics Study on Nevirapine Resistance in Tanzania | NCT00294892
Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots. J Clin Microbiol (2013) 0.87
The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Res (2012) 0.76
Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12
Mortality after fluid bolus in African children with severe infection. N Engl J Med (2011) 10.99
Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis (2012) 7.18
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis (2011) 5.94
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis (2010) 4.41
Multilocus sequence typing of Clostridium difficile. J Clin Microbiol (2009) 4.16
A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open (2012) 3.93
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis (2011) 3.16
Whole-genome sequencing shows that patient-to-patient transmission rarely accounts for acquisition of Staphylococcus aureus in an intensive care unit. Clin Infect Dis (2013) 3.05
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe. Clin Infect Dis (2010) 2.74
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health (2005) 2.68
Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis (2005) 2.64
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol (2004) 2.59
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses (2008) 2.41
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis (2012) 2.26
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst (2003) 2.25
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med (2009) 2.16
Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis (2011) 2.13
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One (2011) 2.04
Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol (2012) 2.04
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
WHO guidelines on fluid resuscitation in children: missing the FEAST data. BMJ (2014) 2.00
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med (2014) 2.00
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis (2008) 1.98
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey. PLoS Med (2010) 1.89
Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis (2004) 1.84
The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS (2008) 1.81
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol (2010) 1.76
Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr (2008) 1.75
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis (2009) 1.73
Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr (2002) 1.70
Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol (2002) 1.69
Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS (2004) 1.67
Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther (2009) 1.66
Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr (2006) 1.62
The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis (2007) 1.61
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther (2002) 1.61
Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS (2012) 1.59
Clostridium difficile mixed infection and reinfection. J Clin Microbiol (2011) 1.59
Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS (2008) 1.58
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr (2003) 1.57
Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial. BMC Med (2013) 1.57
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis (2002) 1.56
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS (2008) 1.55
Increasing antiretroviral drug access for children with HIV infection. Pediatrics (2007) 1.54
Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation (2005) 1.54
Increased detection of respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses with real-time PCR in samples from patients with respiratory symptoms. J Clin Microbiol (2007) 1.51
Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis (2012) 1.51
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Transmission networks of HIV-1 among men having sex with men in the Netherlands. AIDS (2010) 1.49
Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol (2005) 1.48
Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther (2011) 1.48
Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthalmol (2006) 1.47
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med (2012) 1.44
Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS One (2011) 1.43
Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS (2007) 1.41
Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis (2011) 1.40
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis (2012) 1.39
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. Ned Tijdschr Geneeskd (2013) 1.39
Detection of mixed infection from bacterial whole genome sequence data allows assessment of its role in Clostridium difficile transmission. PLoS Comput Biol (2013) 1.38
Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther (2007) 1.38
Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2008) 1.37
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther (2008) 1.36
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS (2008) 1.36
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One (2012) 1.33
Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J (2006) 1.33